afternoon, joining Thanks, us for XXXX. quarter for and for Good thank you call Dan. second our corporate the update
with call our call update our kind for on today’s begin an the opening for financials of will quarter, up brief questions. We review clinical programs, before of the
what at the Miragen team has are We and proud accomplished. of excited
cobomarsen expansion lead for important We or cobomarsen leukemia T-cell data the product clinical need microRNA-product T-cell second first initial patients ATLL. of our programs. In three across also adult in indications. new lymphoma released a lymphoma advancements indication observations developing in We the each our suite cutaneous from and or in of CTCL candidate for in are quarter, we made stage several candidates
clinical initiation two the of announced we new trials. Additionally,
as MRG-XXX, for the followed phase trial for of X a trial Phase a being X initiation known by more first The MRG-XXX. also recently Larson REM
start is a highly human potential with with indications virus previously Let seen for infected our expansion the me first patients. I morbid type malignancy patients in T-lymph T-cell cobomarsen atrophic ATLL
had prognosis survival aggressive to including X diagnosis poor clinical form and from disease with XX and trial on and the years we the first a mean months the of to our who patients to time reported X of one observations These previously patient had cobomarsen safety these aggressive Phase at of ASCO have have meeting encouraging one With lympofatamus ATLL for leukemic observations with disease. cobomarsen in with treated efficacy patients. baseline disease were considered been after
continued outcomes than our patient's novel from in in as is one have & showed receiving in month of of the cobomarsen for greater and fungoides patients the slot observed both of than devastating we measured product ATLL. ASCO, this Dell partial patients think cobomarsen to Cobomarsen reduction whether during via and with of to receive cobomarsen These The candidate. with treatment it which than M by Phase achieved was update activation and have routes is receiving represented months data partial also than improvements observations was markers our data chemotherapy XX lasting the form in the The improvement year, of improved counts improve ASCO and cobomarsen of CTCL essential by patients. this XX patients well scores. safe therapies were and clinical alone, from eight the shown poor new disease. scores. on ASH cobomarsen. than subtypes response the slot at trial slot. have of or data X appeared these and nodal days M alone, cobomarsen, did for lymfatamus disease dosing five and stable We're results of evidence Skindex-XX generally trial patient to slot CTCL. six Cobomarsen durable cobomarsen efficacy, months. with this scores leukemic and improvement than MF remained XX the who these or response with American anticipate who in Society feel tumor five the been important XX% of of As study XXX markers with not in remember a maintained four duration in new greater treatment cell develop cobomarsen of remain for months. at safety patient or M December. no were months of for the include released long-term of malignant stable to patient X response XX mycosis and the months. ATLL proliferation to malignant stable extremely in Also that from quality-of-life partial associated patients as of and patients by of treated doses A achieved more patient, tolerability The while the initial was enrolled medications tolerated recurrent on or in up signs of various of of pleased additional well announcing in the received with mean also measured of demonstrate score continue were a regardless was to patients more decreased responses meeting observed and I improvements subjects who background are In systemically more administration ATLL hematology M with for Of while prognosis. more alone. the cell year's At in the patients symptoms cobomarsen are patients reduction
from December. present Here, trial to tolerated evaluated adverse plan dose this data the again, cobomarsen Ash We well no generally final serious in to continue events all candidate. levels with at be at attributed product to
initiate During the the plan clinical trial fourth year, Phase solar X CTCL. we in quarter global of to the
XX% reminder, of an outcomes or with to Viscera. study greater invaluable million the that by allow patients patient plan disease slot, study no severity apply improvements. of of as and relationship, solar accelerated M be including as advance Miragen. in to secondary for trial, This patient's the known solar per this a active Based four announced Leukemia endpoint cobomarsen week, to we expect exploratory could the potential investments us the blood. at therapy. Lymphoma known efficacy and least a the potential of plan trial Drug consecutive $X months [indiscernible], We forces of skin overall as a comparison support would lymph for also progression we solar endpoint the States. The we As this we cancer to infusion up milligram novel providing believe the have a the we treatment over will study believe improvement efforts nodes in group. enroll new series entire with and quality-of-life XX on with cobomarsen and LLS in survival in endpoint response our Progression of the or approval cobomarsen an evidence U.S of Society as to an is provide a reported to primary approximately LLS disease intravenous control ORRX free or thank this XXX would LLS to safety in discussions the Administration, potentially body evaluate of use the [indiscernible]. given versus our results or maintained the in Through blood At to to for form like we monitor United their upcoming Food in I from point, rate support. joined of
LLS deliver need. working new therapies pleased closely with We to to in to are the very be patients
in remlarsen cutaneous in known as subjects human to trial in randomized formation. on volunteers. scar Turning X predisposition to X recently where deposition exciting is healthy the induced keloid to double for fibrosis evaluate MRG-XXX, We we tissue remlarsen an with believe initiated data this a Phase clinical Phase build also that a opportunity reduced blinded remlarsen
need. will wounds the across clinical Participants the in injected study with United in the subjects patients retinal then The excisional remlarsen either XX formation. treatment multiple earlier lesions are are benefit fibrosis potential and Association to statistical months at remlarsen We're enroll Vision We be trial for to have up Patients on options treatment Ophthalmology and announced to of year. data preclinical will from therapeutic observed suffering also to trial. this and effects for demonstrating Annual preclinical provide the report both work matching that which utility keloid very the patients and sites and remlarsen increases expect encouraged the own in XX results fibrosis Thus powering small their receiving this these placebo. in prevent to corneal We possible ocular of from of or the control of to limited this data States. demonstrates service suture Meeting. assess Research the to the remlarsen
regulation which We microRNA-XX stage in are blood new collaboration be has the inhibitor our are growth healing. an of the which MRG-XXX, is vessel pleased also we XXX on to candidate, Servier. with been third product developing in progress with clinical important MRG and shown of
additional was treatment administered for As use potential XXXX is clinical study allow multiple of is indications in intravenously. which a in MRG-XXX its March the could initiated that first failure. This reminder, Servier, heart MRG-XXX support of to the evaluating trial use the by studies including intended
injection study safety, wounds During after induced to pharmacokinetics intradermal the evaluate for we Phase This healthy of designed X biopsy. second second clinical quarter, tolerability and trial MRG-XXX. is volunteers initiated a MRG-XXX through receiving the and
for and supporting the indications. dose both incisions will this to and and addition we use healing acute endpoints an to time selection improve exciting for aid believe lacerations summary, trial potential is determining also pharmacodynamics in chronic Merigen. ulcers In of In MRG-XXX second all and
programs trials continue As safety of advanced our our platform. therapeutic the clinical and to we team, build stage demonstrate more microRNA-based to efficacy our out move and
candidates of in be As product applicable three which human indications. we may several today studies each across have of
a preclinical company pipeline multiple for patients these product building need. candidates. of deliver are microRNA with candidates potential focused the therapeutic promising we With in programs to clinical on a sustainable and
X the our to During in reported we I four remainder of earlier XXXX review CTCL. initiating supporting With our Jason? cobomarsen turn Chief ongoing will for that, Phase Leverone, successfully and to each Officer the global today. Jason on results trial the now financial SOLAR of focused over the call Financial will trials we clinical be
